Gilead Sciences, Inc. $GILD Position Lifted by Lido Advisors LLC

Lido Advisors LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% in the third quarter, Holdings Channel.com reports. The fund owned 159,191 shares of the biopharmaceutical company’s stock after buying an additional 5,366 shares during the quarter. Lido Advisors LLC’s holdings in Gilead Sciences were worth $23,728,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in GILD. Client 1ST Advisory Group LLC grew its stake in shares of Gilead Sciences by 4.0% during the 3rd quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 69 shares during the period. Bfsg LLC increased its holdings in shares of Gilead Sciences by 7.7% in the 3rd quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 72 shares in the last quarter. Grove Bank & Trust increased its holdings in shares of Gilead Sciences by 1.2% in the 3rd quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company’s stock valued at $946,000 after purchasing an additional 74 shares in the last quarter. Wilkerson Advisory Group LLC lifted its stake in shares of Gilead Sciences by 54.2% in the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 78 shares during the period. Finally, HBW Advisory Services LLC lifted its stake in shares of Gilead Sciences by 2.4% in the first quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company’s stock valued at $473,000 after purchasing an additional 79 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00. Following the sale, the insider directly owned 118,234 shares in the company, valued at $16,273,727.76. This represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director directly owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 242,709 shares of company stock worth $39,503,427 in the last three months. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Down 0.7%

Gilead Sciences stock opened at $169.73 on Thursday. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The firm has a market capitalization of $210.52 billion, a price-to-earnings ratio of -53.71 and a beta of 0.35. The stock’s fifty day moving average is $154.40 and its two-hundred day moving average is $141.51. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business’s revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.47 EPS. Analysts predict that Gilead Sciences, Inc. will post -0.98 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is presently -103.80%.

Key Headlines Impacting Gilead Sciences

Here are a few of the latest headlines about GILD:

• Positive Sentiment: Gilead reported PURPOSE 5 results showing twice-yearly injectable lenacapavir outperformed daily oral HIV prevention on persistence, with no HIV infections in the injectable group. The findings could strengthen the long-term opportunity for its HIV prevention franchise. Gilead Sciences Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
• Positive Sentiment: Recent coverage also points to clinical progress in HIV and liver disease and raised full-year guidance, supporting confidence in Gilead’s outlook. Its latest reported quarter beat analyst estimates for earnings and revenue, with revenue up year over year. Gilead Sciences After Trial Wins And Raised Guidance Looks Fully Valued
• Negative Sentiment: Potential U.S. drug-price negotiations pose a near-term risk to Gilead’s revenue, adding a policy overhang even as its clinical and commercial prospects improve. Drug Pricing Risks As Washington Turns Up Heat

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GILD. Barclays lowered their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Morgan Stanley increased their target price on shares of Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Citigroup lifted their price target on shares of Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Wells Fargo & Company boosted their price target on Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, Royal Bank Of Canada boosted their price target on Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research note on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.15.

Gilead Sciences Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.